This is an aggregated industry headline. Read the full story at FierceBiotech →
'I wouldn't call it a blip': Biotech IPOs here to stay after another record-breaking listing
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.
By FierceBiotech
· Jun 13, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekFierceBiotech ↗
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
The WeekBriefing
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…